

## HEALTHCARE MONTHLY

**APRIL 2021** 

Our healthcare team architects market-defining outcomes for some of the world's most innovative medical device, life science, diagnostics, healthcare services and pharmaceutical companies

BioTech / Pharma

Healthcare Services

Life Sciences / Diagnostics

**Medical Devices** 

### **HEADLINE TRANSACTIONS**


	TARGET	ACQUIROR	ACQUISITION SYNOPSIS
Healthcare Services	Community Care	NCP NORTHLANE CAPITAL PARTNERS	<ul> <li>TM Capital served as exclusive financial advisor to Empower Community Care in connection with an investment from Northlane Capital Partners</li> <li>Empower is a leading global behavioral health organization offering proprietary, scientifically-proven treatments, software and services to help at-risk youth, their families and caregivers</li> <li>Northlane is a private equity firm whose principals have invested more than \$1.5 billion in the healthcare and business services sectors</li> </ul>
Healthcare Services	Q <sup>2</sup> Solutions	€QVIA	<ul> <li>IQVIA (NYSE:IQV), owner of 60% of Q2 Solutions, agreed to acquire the remaining 40% stake in Q2 from Quest Diagnostics (NYSE:DGX)</li> <li>Q2 Solutions is a leading global clinical laboratory services organization that provides comprehensive testing, biorepository and biospecimen solutions for clinical trials</li> <li>IQVIA is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry</li> <li>Total consideration: \$760 million in cash for a 40% stake, representing a \$1.9 billion enterprise value</li> </ul>
Medical Devices	Global surgery buisness of Lumenis Ererar to Healthcure	Boston Scientific	<ul> <li>Boston Scientific (NYSE:BSX) entered into a definitive agreement to acquire the Global Surgical Business of Lumenis</li> <li>The Global Surgical Business manufactures laser systems and fibers used in urology and otalaryngology procedures</li> <li>Boston Scientific develops and manufactures medical devices for various medical specialties worldwide</li> <li>Total consideration: \$11 billion in cash</li> </ul>
Life Sci / Diagnostics	Luminex.	DiaSorin Molecular	<ul> <li>DiaSorin S.p.A (BIT:DIA) entered into a definitive agreement to acquire Luminex Corporation (NasdaqGS:LMNX)</li> <li>Luminex develops proprietary biological testing products for diagnostics, pharmaceutical, and research industries worldwide</li> <li>DiaSorin develops immunodiagnostics and molecular diagnostics</li> <li>Total consideration: \$1.8 billion in cash (23% premium)</li> <li>Implied Enterprise Value: 4.2x LTM Revenue, 21.4x LTM EBITDA</li> </ul>




# HEALTHCARE GROWTH & VALUATION TRENDS




#### Enterprise Value / LTM Revenue




#### **Enterprise Value / LTM EBITDA**



#### LTM Revenue Growth




#### LTM Gross and EBITDA Margins\*



\*EBITDA Margins shown as the gray line.



#### LTM Stock Price Index





## SELECTED HEALTHCARE TRANSACTIONS

Target	Acquiror	BioTech / Pharma Transactions
Five Prime (NasdaqGS:FPRX)	Amgen Inc. (NasdaqGS:AMGN)	Five Prime is a biotechnology company focusing on the development of immuno-oncology and targeted cancer therapies Total consideration: \$1.7 billion in cash (78.7% premium) Implied Enterprise Value / LTM Total Revenue Multiple: 125.4x
Maverick Therapeutics, Inc.	Takeda Pharmaceutical Company Limited	Maverick Therapeutics develops T-cell engagement therapeutics for treating cancer Total consideration: \$525 million in cash
Silicon Therapeutics LLC	Roivant Sciences, Inc.	Silicon Therapeutics is a provider of drug discovery services Total consideration: \$450 million in equity

Target	Acquiror	Life Sci / Diagnostics Transactions
Resolution Bioscience, Inc.	Agilent Technologies, Inc (NYSE:A)	Resolution develops a non-invasive liquid biopsy platform that improves cancer diagnostics and monitoring for patients Total consideration: \$695 million in cash
Asuragen, Inc.	Bio-Techne Corporation (NasdaqGS:TECH)	Asuragen is a molecular diagnostic products company focused on the genetics and oncology markets Total consideration: \$320 million in cash
MatTek Corporation	Cellink AB (CLNK-B:ST)	MatTek Corporation produces ready-to-use normal/non- transformed skin, eye, tracheal/bronchial, and other human cell-derived 3-D organotypic in vitro tissue equivalents Total consideration: \$72 million in cash

Acquiror	Health Services Transactions
Agiliti Health (NYSE:AGTI)	Northfield Medical provides medical device and surgical instrument repairs to acute care and alternative site providers across the United States Total Consideration: \$475 in cash and equity
Platinum Equity	NDC is a healthcare supply chain company and distributo of consumable healthcare supplies
SOC Telemed, Inc. (NasdaqGS:TLMD)	Access is a multispecialty physician group offering inpatient telemedicine in the US Total consideration: \$194 million in cash and equity
Acquiror	Medical Device Transactions
Organon & Co.	Alydia Health, Inc. designs and manufactures medical devices for preventing maternal morbidity and mortalit caused by postpartum hemorrhage Total consideration: \$240 million in cash and equity
Hellman & Friedman LLC	Cordis develops interventional medical devices for cardiovascular, endovascular, and biliary duct (liver) treatments Total consideration: \$1 billion in cash
	Agiliti Health (NYSE:AGTI) Platinum Equity SOC Telemed, Inc. (NasdaqGS:TLMD) Acquiror

#### TM Capital's Healthcare Industry Contacts

#### Selected TM Capital Healthcare Experience









James McLaren Managing Director jmclaren@tmcapital.com 212.809.1414



John Dean Principal jdean@tmcapital.com 404.995.6234



Michael Goldman Managing Director mgoldman@tmcapital.com 212.809.1419



Steve Hunter Managing Director, Sponsor Coverage shunter@tmcapital.com 404.995.6232



Paul Smolevitz Managing Director psmolevitz@tmcapital.com 212.809.1416



